Dr. Lal Path Labs · NSE: LALPATHLAB · BSE: 539524
Q1 FY22 results · Apr–Jun 2021
Dr. Lal Path Labs reported revenue from operations of ₹606.60 crore (up 128.0% from Q1 FY21) and net profit of ₹133.70 crore (up 370.8% from Q1 FY21) for Q1 FY22 (Apr–Jun 2021), on a consolidated basis.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 606.60 | 266.00 | +128.0% | 431.00 | +40.7% |
| Other income | 14.10 | 11.40 | +23.7% | 13.50 | +4.4% |
| Total income | 620.70 | 277.40 | +123.8% | 444.50 | +39.6% |
| Profit before tax | 179.30 | 38.10 | +370.6% | 110.80 | +61.8% |
| Net profit for the period | 133.70 | 28.40 | +370.8% | 85.10 | +57.1% |
| Attributable to shareholders of the company | 131.20 | 28.40 | +362.0% | 83.40 | +57.3% |
| EPS, basic (₹) | 15.87 | 3.45 | +360.0% | 10.10 | +57.1% |
| Net margin (%) | 22.0 | 10.7 | 19.7 |
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 564.90 | 255.00 | +121.5% | 404.10 | +39.8% |
| Other income | 13.50 | 11.10 | +21.6% | 13.10 | +3.1% |
| Total income | 578.40 | 266.10 | +117.4% | 417.20 | +38.6% |
| Profit before tax | 165.20 | 38.50 | +329.1% | 104.70 | +57.8% |
| Net profit for the period | 123.30 | 28.80 | +328.1% | 78.70 | +56.7% |
| EPS, basic (₹) | 14.93 | 3.50 | +326.6% | 9.52 | +56.8% |
| Net margin (%) | 21.8 | 11.3 | 19.5 |
Consolidated
- Filed with BSE
- 30 Jul 2021, 16:01 IST
- Board meeting
- 30 Jul 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 Jul 2021, 16:01 IST
- Board meeting
- 30 Jul 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE